Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_federal_law
|
| gptkbp:amends |
gptkb:Federal_Food,_Drug,_and_Cosmetic_Act
multiple times |
| gptkbp:appliesTo |
generic pharmaceuticals
brand-name pharmaceuticals |
| gptkbp:associated_with |
generic drug manufacturers
brand-name drug manufacturers the pharmaceutical supply chain |
| gptkbp:challenges |
in courts
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| gptkbp:encourages |
research and development in pharmaceuticals
|
| gptkbp:facilitates |
abbreviated new drug applications (ANDAs)
|
| gptkbp:has_a_focus_on |
healthcare_reform_discussions
|
| gptkbp:has_implications_for |
patient access to medications
drug innovation |
| gptkbp:hasConflictWith |
over patent validity
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hatch-Waxman Act
|
| gptkbp:impact |
pharmaceutical industry
pharmaceutical patent strategies |
| gptkbp:influenced |
international drug policy discussions
|
| gptkbp:influences |
drug pricing
|
| gptkbp:involves |
patent litigation provisions
|
| gptkbp:is_a_key_component_of |
the_U.S._drug_approval_system
|
| gptkbp:is_a_model_for |
other countries' drug laws
|
| gptkbp:is_a_subject_of |
public policy debates
academic research legislative review political scrutiny legal analysis |
| gptkbp:is_essential_for |
public health
generic drug approval. |
| gptkbp:is_involved_in |
trade agreements
|
| gptkbp:is_linked_to |
drug safety regulations
|
| gptkbp:is_part_of |
U.S._healthcare_policy
the_U.S._legal_framework_for_pharmaceuticals |
| gptkbp:is_referenced_in |
healthcare_policy_debates
|
| gptkbp:is_studied_in |
economic studies of drug markets
|
| gptkbp:is_used_in |
congressional hearings
legal cases regarding drug patents pharmaceutical law courses |
| gptkbp:landmark |
legislation in drug policy
|
| gptkbp:led_to |
increased availability of generic drugs
|
| gptkbp:mandates |
patent term extensions
|
| gptkbp:operates_in |
gptkb:Food_and_Drug_Administration_(FDA)
|
| gptkbp:previousName |
Drug Price Competition and Patent Term Restoration Act
|
| gptkbp:promotes |
competition in drug market
|
| gptkbp:provides |
market exclusivity for brand-name drugs
|
| gptkbp:purpose |
to encourage the development of generic drugs
|
| gptkbp:reduces |
time for generic drug approval
|
| gptkbp:related_to |
intellectual property law
biologics regulation drug approval processes pharmaceutical regulation |
| gptkbp:was_a_factor_in |
drug patent expirations
generic drug pricing strategies |
| gptkbp:was_a_response_to |
high drug prices
|
| gptkbp:yearEstablished |
1984
|